Description
Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan). It was approved for use in the United States in December 2019.